KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBT Margin (2018 - 2025)

Historic EBT Margin for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to 10.16%.

  • Adaptive Biotechnologies' EBT Margin rose 792800.0% to 10.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.49%, marking a year-over-year increase of 787000.0%. This contributed to the annual value of 89.18% for FY2024, which is 431400.0% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its EBT Margin stood at 10.16% for Q3 2025, which was up 792800.0% from 43.47% recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' EBT Margin ranged from a high of 10.16% in Q3 2025 and a low of 620.92% during Q2 2023
  • Its 5-year average for EBT Margin is 131.39%, with a median of 113.52% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -5016300bps in 2023, then soared by 5138400bps in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' EBT Margin (Quarter) stood at 161.76% in 2021, then skyrocketed by 55bps to 72.77% in 2022, then crashed by -108bps to 151.73% in 2023, then surged by 53bps to 71.04% in 2024, then surged by 114bps to 10.16% in 2025.
  • Its EBT Margin was 10.16% in Q3 2025, compared to 43.47% in Q2 2025 and 56.88% in Q1 2025.